183 related articles for article (PubMed ID: 20941462)
1. Aspirin for the primary prevention of cardiovascular events in patients with peripheral artery disease or diabetes mellitus. Analyses from the JPAD, POPADAD and AAA trials.
Soejima H; Morimoto T; Saito Y; Ogawa H
Thromb Haemost; 2010 Dec; 104(6):1085-8. PubMed ID: 20941462
[No Abstract] [Full Text] [Related]
2. AAA- a further step towards a moratorium for aspirin in the primary prevention.
Minar E
Vasa; 2010 May; 39(2):119-122. PubMed ID: 20521434
[No Abstract] [Full Text] [Related]
3. Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysis.
Butalia S; Leung AA; Ghali WA; Rabi DM
Cardiovasc Diabetol; 2011 Apr; 10():25. PubMed ID: 21453547
[TBL] [Abstract][Full Text] [Related]
4. What have we learned about using aspirin for primary prevention from the ASCEND and ARRIVE trials?
Tousoulis D
Cardiovasc Res; 2019 Feb; 115(2):e15-e16. PubMed ID: 30668678
[No Abstract] [Full Text] [Related]
5. Aspirin in primary prevention: USPSTF recommendations.
Aalbers J
Cardiovasc J Afr; 2010; 21(3):176. PubMed ID: 20532445
[No Abstract] [Full Text] [Related]
6. Aspirin reduces cerebrovascular events in type 2 diabetic patients with poorly controlled blood pressure. Subanalysis from the JPAD trial.
Soejima H; Ogawa H; Morimoto T; Nakayama M; Okada S; Uemura S; Kanauchi M; Doi N; Sakuma M; Jinnouchi H; Sugiyama S; Waki M; Saito Y;
Circ J; 2012; 76(6):1526-32. PubMed ID: 22447019
[TBL] [Abstract][Full Text] [Related]
7. [Use of aspirin for primary prevention of cardiovascular events in diabetic patients--is it justified?].
Benhamou Y; Lévesque H
Rev Med Interne; 2009 Dec; 30(12):1001-3. PubMed ID: 19833416
[No Abstract] [Full Text] [Related]
8. Utility of aspirin therapy in patients with the cardiometabolic syndrome and diabetes.
Gardner M; Palmer J; Manrique C; Lastra G; Gardner DW; Sowers JR
J Cardiometab Syndr; 2009; 4(2):96-101. PubMed ID: 19614796
[TBL] [Abstract][Full Text] [Related]
9. Aspirin for Primary Prevention of Cardiovascular Disease and Renal Disease Progression in Chronic Kidney Disease Patients: a Multicenter Randomized Clinical Trial (AASER Study).
Goicoechea M; de Vinuesa SG; Quiroga B; Verde E; Bernis C; Morales E; Fernández-Juárez G; de Sequera P; Verdalles U; Delgado R; Torres A; Arroyo D; Abad S; Ortiz A; Luño J
Cardiovasc Drugs Ther; 2018 Jun; 32(3):255-263. PubMed ID: 29943364
[TBL] [Abstract][Full Text] [Related]
10. Aspirin for Primary and Secondary Prevention of Cardiovascular Disease.
Godley RW; Hernandez-Vila E
Tex Heart Inst J; 2016 Aug; 43(4):318-9. PubMed ID: 27547141
[No Abstract] [Full Text] [Related]
11. Review of guidelines on primary prevention of cardiovascular disease with aspirin: how much evidence is needed to turn a tanker?
Matthys F; De Backer T; De Backer G; Stichele RV
Eur J Prev Cardiol; 2014 Mar; 21(3):354-65. PubMed ID: 23610452
[TBL] [Abstract][Full Text] [Related]
12. ASPIRIN FOR PRIMARY PREVENTION IN PATIENTS WITH TYPE 2 DIABETES.
Foster JG; Wood SK; Pfeffer MA; DeMets DL; Garber A; Hennekens CH
Endocr Pract; 2018 Oct; 24(10):925-927. PubMed ID: 29975578
[No Abstract] [Full Text] [Related]
13. On the potential contribution of aspirin to healthy ageing programmes.
Morgan GP
Age Ageing; 2016 Mar; 45(2):e1-3. PubMed ID: 22101149
[No Abstract] [Full Text] [Related]
14. Is aspirin still the drug of choice for management of patients with peripheral arterial disease?
Poredos P; Jezovnik MK
Vasa; 2013 Mar; 42(2):88-95. PubMed ID: 23485835
[TBL] [Abstract][Full Text] [Related]
15. Aspirin and the Primary Prevention of Cardiovascular Diseases: An Approach Based on Individualized, Integrated Estimation of Risk.
Volpe M; Battistoni A; Gallo G; Coluccia R; De Caterina R
High Blood Press Cardiovasc Prev; 2017 Sep; 24(3):331-339. PubMed ID: 28573479
[TBL] [Abstract][Full Text] [Related]
16. Aspirin for Primary Prevention of Cardiovascular Disease.
Kheiri B; Barbarawi M; Bachuwa G; Shapiro MD
Circ Cardiovasc Qual Outcomes; 2019 Jun; 12(6):e005846. PubMed ID: 31163982
[No Abstract] [Full Text] [Related]
17. Aspirin for primary prevention of cardiovascular disease in diabetes mellitus.
Pignone M; Williams CD
Nat Rev Endocrinol; 2010 Nov; 6(11):619-28. PubMed ID: 20856266
[TBL] [Abstract][Full Text] [Related]
18. Aspirin Monotherapy Should Not Be Recommended for Cardioprotection in Patients With Symptomatic Peripheral Artery Disease.
Brass EP; Hiatt WR
Circulation; 2017 Aug; 136(9):785-786. PubMed ID: 28847795
[No Abstract] [Full Text] [Related]
19. Review of an article: aspirin for primary prevention of cardiovascular events in people with diabetes. A position statement of the American Diabetes Association (ADA), a scientific statement of the American Heart Association(AHA), and an expert consensus document of the American College of Cardiology Foundation (ACCF). Diabetes Care, 33:6; June 2010; 1395-1402.
Gilpin VL; ; ;
J Vasc Nurs; 2010 Dec; 28(4):154-5. PubMed ID: 21074118
[No Abstract] [Full Text] [Related]
20. Aspirin in a diabetic retinopathy setting: Insights from NO BLIND study.
Pafundi PC; Galiero R; Caturano A; Acierno C; de Sio C; Vetrano E; Nevola R; Gelso A; Bono V; Costagliola C; Marfella R; Sardu C; Rinaldi L; Salvatore T; Adinolfi LE; Sasso FC;
Nutr Metab Cardiovasc Dis; 2020 Sep; 30(10):1806-1812. PubMed ID: 32736957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
